A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Detalles Bibliográficos
Autores principales: Ramirez-Sanchez, Claudia, Kozuch, Jade, Shah, Mita M, Berumen, Jennifer, Mekeel, Kristin, Schnickel, Gabriel, Taremi, Mahnaz, Golts, Eugene, Afshar, Kamyar, Adler, Eric, Pretorius, Victor, Aslam, Saima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679803/
https://www.ncbi.nlm.nih.gov/pubmed/36420058
http://dx.doi.org/10.1093/ofid/ofac550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679803/
https://www.ncbi.nlm.nih.gov/pubmed/36420058
http://dx.doi.org/10.1093/ofid/ofac550

Ejemplares similares